🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Catch tomorrow's UT Health San Antonio IM Residency grand rounds presentation by our very own @DrBarbaraTaylor titled "Can we end the HIV epidemic now? New tools and lessons learned from COVID-19 vaccine development and roll out"! Excited to hear this talk at 8:00 CST on 10/26💡🩺🦠

Look at this cool floret pattern Staph aureus made on this plate 🌼 If anyone has a theory as to why, chime in! #IDtwitter #microplaterounds

Great presentation by our ID pharmacists, Amber Welborn;Emily Kirkpatrick, w/ data on involvement of pharmacists in HIV care-including 🔽 hospitalizations; 🔼 CD4 upto 60 cells/mm3; 🔼 adherence. To catch case presentation by our ID fellow, tune in now! UT Health San Antonio AETC University Health Pharmacy Residency Programs

Happy Halloween from UT health! 🦠👻💉 Check out our COVID bundle: vaccine vial; paxlovid; SARS CoV-2; & COVID vaccine!!

Check out the poster on "Flea-borne typhus causing HLH" at #astmh2022 at noon today, by fellow Divya Chandramohan, faculty mentor Gregory Anstead 🦠 Log in to the chat function and post your qs virtually #IDtwitter!

Excited for our first in-person City Wide Bug Club in a long time UT Health San Antonio AETC 🎊 Sign up 👇🏼 See you all at La Quinta this evening! scaetc.unm.edu/scaetc/event/?…

medium.com/authority-maga…

ID UT health team at holiday luncheon this time of the year! UT Health San Antonio Happy holidays! 🎉🎁🎈

Best wishes for a happy, healthy, and joyous holiday season! 🎅🏼🎄🎊

Get ready for another excellent in-person bug 🦠club with UT Health San Antonio AETC this evening at La Quinta 👈🏼👩🏼‍⚕️🧑🏽‍⚕️#idtwitter #texasid

We are thrilled to welcome our 2024 Infectious Diseases fellows! We still have one spot available. If interested please email [email protected] for more information.

Looking forward to reviewing the data! 🤓 #excited

Next up: DOTS trial studying dalbavancin vs SOC for SAB (33% MRSA). Primary outcome DOOR at day 70, designed as superiority analysis. Good mix of infection sources including endovascular. ESCMID #ESCMIDGlobal2024

We look forward to having you all on board!